Personalized participatory medicine: Sharing knowledge and uncertainty

Genome Medicine

Volumn 3, Issue 10, 2011, Pages

  Gurwitz, David ^a   Lunshof, Jeantine E ^b,c,d  

^a TEL AVIV UNIVERSITY   (Israel)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; ENDOXIFEN; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CANCER RECURRENCE; FOLLOW UP; GENOTYPE; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL;

EID: 80054959825     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm285     Document Type: Article

References (10)

1. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med 2003, 348:553-556. 10.1056/NEJMe020173, 12571264.
2. Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, Dewey FE, Dudley JT, Ormond KE, Pavlovic A, Morgan AA, Pushkarev D, Neff NF, Hudgins L, Gong L, Hodges LM, Berlin DS, Thorn CF, Sangkuhl K, Hebert JM, Woon M, Sagreiya H, Whaley R, Knowles JW, Chou MF, Thakuria JV, Rosenbaum AM, Zaranek AW, Church GM, Greely HT, Quake SR, et al. Clinical assessment incorporating a personal genome. Lancet 2010, 375:1525-1535. 10.1016/S0140-6736(10)60452-7, 2937184, 20435227.
3. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011, 364:1144-1153. 10.1056/NEJMra1010600, 21428770.
4. Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, Ziv E. Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med 2011, 3:64. 10.1186/gm280, 21970596.
5. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007, 101:113-121. 10.1007/s10549-006-9428-0, 17115111.
6. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302:1429-1436. 10.1001/jama.2009.1420, 19809024.
7. Seruga B, Amir E. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat 2010, 122:609-617. 10.1007/s10549-010-0902-3, 20454926.
8. Siegelmann-Danieli N, Kurnik D, Lomnicky Y, Vesterman-Landes J, Katzir I, Bialik M, Loebstein R. Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 2011, 125:505-510. 10.1007/s10549-010-1008-7, 20593233.
9. Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick RJ. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther 2011, 90:605-611. 10.1038/clpt.2011.153, 21900890.
10. Ahmad A, Shahabuddin S, Sheikh S, Kale P, Krishnappa M, Rane RC, Ahmad I. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther 2010, 88:814-817. 10.1038/clpt.2010.196, 20981001.